PMC4020624_01
(A) Clincial timeline for the development of Carbamazepine associated TEN in the case study patient. (B) Negative petrolatum control and positive patch test for 0.1%-10% carbamazepine in the patient 9.5 years after the original TEN reaction (left) and positive PBMC INF-g Elispot for 5-10ug/mL carbamazepine for 100 000 cells/well for a sample taken 17 years after the clinical TEN reaction (right). Positive controls (CD3+ and CEF peptide pool) and unstimulated PBMCs are also shown.
nihms-544572-f0002.jpg
PMC4020624_01_nihms-544572-f0002.jpg
F1
Follow-up two weeks after discharge revealed her to have healing skin with normalization of liver function and cessation of trigeminal pain (Figure 1A). TEN when she was still virologically suppressed on Trizivir were strongly positive for all concentrations of carbamazepine and negative for petrolatum control (Figure 1B). The patient also had multiple positive INFgamma ELISpot with PBMCs stimulated with carbamazepine with the last being over 17 years following the initial TEN diagnosis (Figure 1B).